138 related articles for article (PubMed ID: 32234364)
1. Combining Adjuvant Radiotherapy With Capecitabine in Chemotherapy-resistant Breast Cancer: Feasibility, Safety, and Toxicity.
Sherry AD; Mayer IA; Ayala-Peacock DN; Abramson VG; Rexer BN; Chakravarthy AB
Clin Breast Cancer; 2020 Aug; 20(4):344-352.e1. PubMed ID: 32234364
[TBL] [Abstract][Full Text] [Related]
2. Toxicity after adjuvant therapy for stage III uterine cancer.
Chen LC; Huang Y; Hou JY; Khoury-Collado F; Melamed A; St Clair CM; Tergas AI; Hur C; Hillyer GC; Hershman DL; Wright JD
Gynecol Oncol; 2020 Dec; 159(3):737-743. PubMed ID: 33008633
[TBL] [Abstract][Full Text] [Related]
3. Feasibility and Tolerability of Adjuvant Capecitabine-Based Chemoradiation in Patients With Breast Cancer and Residual Disease After Neoadjuvant Chemotherapy: A Prospective Clinical Trial.
Balbach ML; Sherry AD; Rexer BN; Abramson VG; Niermann KJ; Johnson CR; Park BH; Mayer IA; Chakravarthy AB
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1262-1270. PubMed ID: 37433376
[TBL] [Abstract][Full Text] [Related]
4. Concurrent use of capecitabine with radiation therapy and survival in breast cancer (BC) after neoadjuvant chemotherapy.
Liu YL; Chin C; Catanese B; Lee SM; Zhan S; Kalinsky K; Connolly EP
Clin Transl Oncol; 2018 Oct; 20(10):1280-1288. PubMed ID: 29594944
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of relatively low neoadjuvant radiation doses for locally advanced rectal cancer: A propensity score-matched analysis.
Ye W; Shi L; Qian L; Sun Y; Sun X
Cancer Rep (Hoboken); 2019 Oct; 2(5):e1188. PubMed ID: 32721108
[TBL] [Abstract][Full Text] [Related]
6. Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy.
Chang H; Tao YL; Jiang W; Chen C; Liu SL; Ye WJ; Gao YH
BMC Cancer; 2020 Jun; 20(1):498. PubMed ID: 32487091
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine and stereotactic radiation in the management of breast cancer brain metastases.
Mills MN; Naz A; Thawani C; Walker C; Figura NB; Kushchayev S; Oliver DE; Etame AB; Yu HM; Robinson TJ; Liu JKC; Vogelbaum MA; Forsyth PA; Czerniecki BJ; Soliman HH; Han HS; Ahmed KA
BMC Cancer; 2021 May; 21(1):552. PubMed ID: 33992087
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine as a Radiosensitizer in Adjuvant Chemoradiotherapy for Pancreatic Cancer: A Retrospective Study.
Abrams MJ; Huber KE; Knisely JP; Chang BW; Russo SM; Saif MW
Anticancer Res; 2015 Dec; 35(12):6901-7. PubMed ID: 26637914
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab and Hypofractionated Whole Breast Radiotherapy: A Victorious Combination?
De Santis MC; Bonfantini F; Di Salvo F; Fiorentino A; Riboldi VM; Di Cosimo S; Bianchi GV; Gennaro M; Cosentino V; Sant M; Pignoli E; Valdagni R; Lozza L
Clin Breast Cancer; 2018 Jun; 18(3):e363-e371. PubMed ID: 28958838
[TBL] [Abstract][Full Text] [Related]
10. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
11. Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial.
Feng YR; Zhu Y; Liu LY; Wang WH; Wang SL; Song YW; Wang X; Tang Y; Liu YP; Ren H; Fang H; Zhang SP; Liu XF; Yu ZH; Li YX; Jin J
Oncotarget; 2016 May; 7(18):25576-84. PubMed ID: 27014909
[TBL] [Abstract][Full Text] [Related]
12. Hypofractionated whole breast radiotherapy with or without hypofractionated boost in early stage breast cancer patients: a mono-institutional analysis of skin and subcutaneous toxicity.
Palumbo I; Mariucci C; Falcinelli L; Perrucci E; Lancellotta V; Podlesko AM; Marcantonini M; Saldi S; Bini V; Aristei C
Breast Cancer; 2019 May; 26(3):290-304. PubMed ID: 30341747
[TBL] [Abstract][Full Text] [Related]
13. NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma.
Lee AWM; Ngan RKC; Ng WT; Tung SY; Cheng AAC; Kwong DLW; Lu TX; Chan ATC; Sze HCK; Yiu HHY; Wong FCS; Yuen KT; Chappell R; Choi HCW
Cancer; 2020 Aug; 126(16):3674-3688. PubMed ID: 32497261
[TBL] [Abstract][Full Text] [Related]
14. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma.
Lee AW; Ngan RK; Tung SY; Cheng A; Kwong DL; Lu TX; Chan AT; Chan LL; Yiu H; Ng WT; Wong F; Yuen KT; Yau S; Cheung FY; Chan OS; Choi H; Chappell R
Cancer; 2015 Apr; 121(8):1328-38. PubMed ID: 25529384
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Masuda N; Lee SJ; Ohtani S; Im YH; Lee ES; Yokota I; Kuroi K; Im SA; Park BW; Kim SB; Yanagita Y; Ohno S; Takao S; Aogi K; Iwata H; Jeong J; Kim A; Park KH; Sasano H; Ohashi Y; Toi M
N Engl J Med; 2017 Jun; 376(22):2147-2159. PubMed ID: 28564564
[TBL] [Abstract][Full Text] [Related]
16. Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care.
Meulendijks D; van Hasselt JGC; Huitema ADR; van Tinteren H; Deenen MJ; Beijnen JH; Cats A; Schellens JHM
Eur J Cancer; 2016 Feb; 54():120-130. PubMed ID: 26761784
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study.
Akgun Z; Saglam S; Yucel S; Gural Z; Balik E; Cipe G; Yildiz S; Kilickap S; Okyar A; Kaytan-Saglam E
Cancer Chemother Pharmacol; 2014 Oct; 74(4):751-6. PubMed ID: 25102935
[TBL] [Abstract][Full Text] [Related]
18. New Cardiac Abnormalities After Radiotherapy in Breast Cancer Patients Treated With Trastuzumab.
Nack E; Koffer PP; Blumberg CS; Leonard KL; Huber KE; Fenton MA; Dizon DS; Wazer DE; Hepel JT
Clin Breast Cancer; 2020 Jun; 20(3):246-252. PubMed ID: 32067901
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing acute and late toxicity in the era of adjuvant hypofractionated breast radiotherapy.
De Santis MC; Bonfantini F; Di Salvo F; Dispinzieri M; Mantero E; Soncini F; Baili P; Sant M; Bianchi G; Maggi C; Di Cosimo S; Agresti R; Pignoli E; Valdagni R; Lozza L
Breast; 2016 Oct; 29():90-5. PubMed ID: 27476083
[TBL] [Abstract][Full Text] [Related]
20. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.
Park SH; Sohn TS; Lee J; Lim DH; Hong ME; Kim KM; Sohn I; Jung SH; Choi MG; Lee JH; Bae JM; Kim S; Kim ST; Park JO; Park YS; Lim HY; Kang WK
J Clin Oncol; 2015 Oct; 33(28):3130-6. PubMed ID: 25559811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
